Recordati Rare Diseases develops high-impact therapies for devastating rare diseases. At Recordati, we focus on the few - those affected by rare diseases. They are our top priority and at the core of everything we do.

At this conference, we are excited to share information about FDA-approved CYSTADROPS (cysteamine ophthalmic solution) 0.37%.

To learn more, attend our Virtual Showcase session from 4:15-4:30pm EST on May 3rd & May 4th. We are looking forward to seeing you.

Please see the Full Prescribing Information and Information for Use at www.cystadrops.com.

Cystadrops is a licensed trademark of Recordati Rare Diseases Inc.© 2021 Recordati Rare Diseases Inc.